Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Surprising Reactivity in NiXantphos/Palladium-Catalyzed α-Arylation of Substituted Cyclopropyl Nitriles.

Wright BA, Ardolino MJ.

J Org Chem. 2019 Apr 19;84(8):4670-4679. doi: 10.1021/acs.joc.8b02238. Epub 2018 Nov 19.

PMID:
30412410
2.

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW, Raulet DH, Ardolino M.

J Clin Invest. 2018 Oct 1;128(10):4654-4668. doi: 10.1172/JCI99317. Epub 2018 Sep 10.

3.

Differential Role of Hematopoietic and Nonhematopoietic Cell Types in the Regulation of NK Cell Tolerance and Responsiveness.

Shifrin NT, Kissiov DU, Ardolino M, Joncker NT, Raulet DH.

J Immunol. 2016 Nov 15;197(10):4127-4136. doi: 10.4049/jimmunol.1402447. Epub 2016 Oct 19.

4.

Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells.

Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, Chen MB, Krall JA, DeCock J, Zervantonakis IK, Iannello A, Iwamoto Y, Cortez-Retamozo V, Kamm RD, Pittet MJ, Raulet DH, Weinberg RA.

Cancer Discov. 2016 Jun;6(6):630-49. doi: 10.1158/2159-8290.CD-15-1157. Epub 2016 Apr 12.

5.

Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors.

Ardolino M, Raulet DH.

Oncoimmunology. 2015 Jun 5;5(1):e1002725. eCollection 2016.

6.

Immunosurveillance and immunotherapy of tumors by innate immune cells.

Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH.

Curr Opin Immunol. 2016 Feb;38:52-8. doi: 10.1016/j.coi.2015.11.001. Epub 2015 Dec 11. Review.

7.

Cytokine treatment in cancer immunotherapy.

Ardolino M, Hsu J, Raulet DH.

Oncotarget. 2015 Aug 14;6(23):19346-7. No abstract available.

8.
9.

Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.

Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, Deng W, Ring AM, Fischer S, Garcia KC, Raulet DH.

J Clin Invest. 2014 Nov;124(11):4781-94. doi: 10.1172/JCI74337. Epub 2014 Oct 20.

10.
11.

Congested C-C bonds by Pd-catalyzed enantioselective allyl-allyl cross-coupling, a mechanism-guided solution.

Ardolino MJ, Morken JP.

J Am Chem Soc. 2014 May 14;136(19):7092-100. doi: 10.1021/ja502280w. Epub 2014 Apr 29.

12.

NK cell self tolerance, responsiveness and missing self recognition.

Shifrin N, Raulet DH, Ardolino M.

Semin Immunol. 2014 Apr;26(2):138-44. doi: 10.1016/j.smim.2014.02.007. Epub 2014 Mar 12. Review.

13.

Recognition of tumors by the innate immune system and natural killer cells.

Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH.

Adv Immunol. 2014;122:91-128. doi: 10.1016/B978-0-12-800267-4.00003-1. Review.

14.

A role for host activation-induced cytidine deaminase in innate immune defense against KSHV.

Bekerman E, Jeon D, Ardolino M, Coscoy L.

PLoS Pathog. 2013;9(11):e1003748. doi: 10.1371/journal.ppat.1003748. Epub 2013 Nov 7.

15.

p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells.

Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH.

J Exp Med. 2013 Sep 23;210(10):2057-69. doi: 10.1084/jem.20130783. Epub 2013 Sep 16.

16.

Characterization of a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK cell repertoire.

Sheppard S, Triulzi C, Ardolino M, Serna D, Zhang L, Raulet DH, Guerra N.

Blood. 2013 Jun 20;121(25):5025-33. doi: 10.1182/blood-2012-12-471607. Epub 2013 May 6.

17.

Impact of providing fee data on laboratory test ordering: a controlled clinical trial.

Feldman LS, Shihab HM, Thiemann D, Yeh HC, Ardolino M, Mandell S, Brotman DJ.

JAMA Intern Med. 2013 May 27;173(10):903-8. doi: 10.1001/jamainternmed.2013.232.

PMID:
23588900
18.

Association of self-reported hospital discharge handoffs with 30-day readmissions.

Oduyebo I, Lehmann CU, Pollack CE, Durkin N, Miller JD, Mandell S, Ardolino M, Deutschendorf A, Brotman DJ.

JAMA Intern Med. 2013 Apr 22;173(8):624-9. doi: 10.1001/jamainternmed.2013.3746.

19.

NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses.

Zingoni A, Ardolino M, Santoni A, Cerboni C.

Front Immunol. 2013 Jan 9;3:408. doi: 10.3389/fimmu.2012.00408. eCollection 2012.

20.

Construction of 1,5-enynes by stereospecific Pd-catalyzed allyl-propargyl cross-couplings.

Ardolino MJ, Morken JP.

J Am Chem Soc. 2012 May 30;134(21):8770-3. doi: 10.1021/ja302329f. Epub 2012 May 17.

21.

Diastereocontrol in asymmetric allyl-allyl cross-coupling: stereocontrolled reaction of prochiral allylboronates with prochiral allyl chlorides.

Brozek LA, Ardolino MJ, Morken JP.

J Am Chem Soc. 2011 Oct 26;133(42):16778-81. doi: 10.1021/ja2075967. Epub 2011 Oct 5.

22.

DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction.

Ardolino M, Zingoni A, Cerboni C, Cecere F, Soriani A, Iannitto ML, Santoni A.

Blood. 2011 May 5;117(18):4778-86. doi: 10.1182/blood-2010-08-300954. Epub 2011 Mar 15.

23.

Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.

Cerboni C, Ardolino M, Santoni A, Zingoni A.

Blood. 2009 Mar 26;113(13):2955-64. doi: 10.1182/blood-2008-06-165944. Epub 2009 Jan 5.

24.

Capture and classification of problems during CPOE deployment in an academic pediatric center.

Kim GR, Miller MR, Ardolino MA, Smith JE, Lee DC, Lehmann CU.

AMIA Annu Symp Proc. 2007 Oct 11:414-7.

25.

A computer workstation for clinical medicine.

Lenhard RE, Kahane SN, Richmond DW, Phipps KJ, Ardolino MK, Kearney LA, Lifshitz K.

J Med Syst. 1990 Oct;14(5):227-43.

PMID:
2094750

Supplemental Content

Loading ...
Support Center